Objective
IT IS EXPECTED TO OBTAIN A NEW CLASS OF CLONING VECTORS, WITH INTERESTING PROPERTIES : NOT ONLY THEY ARE NOT ONCOGENIC, BUT THEY MIGHT INHIBIT THE DEVELOPMENT OF SOME TYPES OF TUMORS.
Modification of the genomes of parvoviruses H-1 and MVM, attempting to make them suitable linear vectors, has resulted in:
production of recombinant parvoviruses showing transduction specificity for oncogene-transformed cells and having potential for cancer gene therapy;
programmed cell killing by means of inducible clones of parvoviral genes encoding nonstructural proteins;
demonstration and unravelling of the oncolytic activity of parvoviruses, raising prospects of anticancer applications.
Attempts were made to identify and modify MVM sequences that limit the use of this parvovirus as a vector. An attenuator of virus driven gene expression could be deleted. Since cytotoxic products proved essential for virus replication, a strategy was developed for isolation of cells surviving virus propagation. Oncogenic transformation of a number of human and murine cells enhanced their capacity for expressing MVM and H-1 early genes. The up modulation was especially interesting since these parvoviral nonstructural (NS) proteins were cytotoxic. As a first step towards the construction of an artificial minimchromosome, human deoxyribonucleic acid (DNA) sequences that presumably contain an origin of replication (ori) were isolated, cloned and characterised. However, these sequences no longer functioned as ori after their insertion into circular plasmids, and are now being subcloned in modified parvoviral vectors requiring an exogenous ori for their replication.
THE MOST COMMON GENE VECTOR IS THE CIRCULAR DNA OF BACTERIAL PLASMIDS, WHICH ARE UNABLE TO REPLICATE IN ANIMAL CELLS. GENERALLY, VECTORS FOR ANIMAL CELLS ARE BASED ON ONCOGENIC VIRUSES.
THE PRESENT PROJECT AIMS AT OVERCOMING SUCH LIMITATIONS BY PRODUCING A LINEAR VECTOR CONTAINING PUTATIVE ORIGINS OF MAMMALIAN CELL DNA AND UTILIZING AS FUNCTIONAL TELOMERES THE ENDS OF THE REPLICATIVE FORM OF AUTONOMOUS PARVOVIRUSES.
THESE VIRUSES ARE OF VETERINARY INTEREST, AND VACCINES COULD BE OBTAINED EITHER BY CLONING PARTS OF THEIR GENOME IN E. COLI OR BY MANIPULATING THE VIRUS TO PRODUCE AN APPROPRIATE ANTIGEN IN ANIMAL CELLS. IT IS ALSO PLANNED TO INTRODUCE ANIMAL DNA INTO CONSTRUCTS CONTAINING AT THE TWO ENDS THE TERMINI OF PARVOVIRUS IN ITS REPLICATIVE FORM. ANOTHER INTERESTING PROPERTY OF PARVOVIRUSES IS TO INHIBIT THE DEVELOPMENT OF TUMORS : THE NON PATHOGENIC PARVOVIRAL VECTORS MIGHT BE INTERESTING FOR THIS PURPOSE.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- natural sciences biological sciences microbiology virology
- natural sciences biological sciences genetics DNA
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
1050 BRUSSELS
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.